Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma 4Cardiotoxicity 4Prostatic Neoplasms 3Lung Neoplasms 3Hematologic Neoplasms 3Heart Failure 3Small Cell Lung Carcinoma 2Multiple Myeloma 2Leukemia 2Carcinoma in Situ 2Breast Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Ventricular Dysfunction, Left 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Sleep Initiation and Maintenance Disorders 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Peritoneal Neoplasms 1Papillomavirus Infections 1Ovarian Neoplasms 1Nose Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Metastatic Solid Tumors 1Metabolic Syndrome 1

Interventions

Dexamethasone 363Bortezomib 232Lenalidomide 202Cyclophosphamide 174Melphalan 154Calcium Dobesilate 107Peripheral Blood Stem Cell Transplantation 92fludarabine phosphate 84Thalidomide 81Filgrastim 71carfilzomib 68pomalidomide 66Granulocyte Colony-Stimulating Factor 60Mycophenolic Acid 59Busulfan 57daratumumab 55Whole-Body Irradiation 54Tacrolimus 51ixazomib 50Prednisone 50Cyclosporine 49fludarabine 46Antilymphocyte Serum 35Etoposide 30dexamethasone acetate 29Methotrexate 29plerixafor 27Radiotherapy 26Doxorubicin 26dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Multiple Myeloma × Electrocardiography × Clear all
NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT04847050 2024-08-27

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
19 enrolled 18 charts
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡